静脉戈利木单抗治疗活动性银屑病关节炎一年疗效与安全性
GO-VIBRANT 是一项 III 期随机安慰剂对照试验,纳入 480 例活动性银屑病关节炎成人患者,随机接受静脉安慰剂或戈利木单抗 2 mg/kg,安慰剂组在第 24 周交叉至戈利木单抗。第 52 周时两组 ACR20 应答率分别为 76.8% 和 77.0%,PASI75 应答率分别为 71.9% 和 60.6%,总 Sharp/van der Heijde 评分平均变化分别为 -0.5 和 0.8。至第 60 周,所有戈利木单抗治疗患者中 50.9% 发生至少 1 次不良事件,5.2% 发生至少 1 次严重不良事件,未发现新的安全性信号。
要点
- 静脉戈利木单抗治疗活动性银屑病关节炎的关节和皮肤疗效可维持至 1 年
- 第 52 周戈利木单抗组 ACR20/50/70 应答率分别为 76.8%/58.1%/38.6%
- 至第 60 周未发现静脉戈利木单抗新的安全性信号
核心结论
- GO-VIBRANT 研究中静脉戈利木单抗治疗活动性银屑病关节炎的关节和皮肤改善可维持至 1 年,未发现新的安全性信号。
研究设计与样本
- GO-VIBRANT 是一项 III 期随机安慰剂对照试验,纳入 480 例活动性银屑病关节炎成人患者。
- 患者随机接受静脉安慰剂(n=239)或戈利木单抗 2 mg/kg(n=241),分别在第 0、4 周及此后每 8 周给药,安慰剂组在第 24、28 周及此后每 8 周交叉至戈利木单抗。
- 疗效评估至第 52 周,不良事件监测至第 60 周。
主要发现
- 第 52 周时戈利木单抗组和安慰剂交叉组分别有 76.8% 和 77.0% 的患者达到 ACR20 应答。
- 第 52 周时戈利木单抗组和安慰剂交叉组分别有 58.1% 和 53.6% 达到 ACR50 应答,38.6% 和 33.9% 达到 ACR70 应答。
- 在基线体表面积受累≥3% 的患者中,第 52 周戈利木单抗组和安慰剂交叉组分别有 71.9% 和 60.6% 达到 PASI75 应答。
- 第 52 周总 Sharp/van der Heijde 评分自基线平均变化在戈利木单抗组为 -0.5,在安慰剂交叉组为 0.8。
- 至第 60 周,所有戈利木单抗治疗患者中 50.9% 发生至少 1 次不良事件,5.2% 发生至少 1 次严重不良事件,未报告机会性感染,发生 2 例恶性肿瘤和 1 例死亡。
关键数值与推荐
- ACR20/50/70 应答标准用于评估关节疗效,PASI75 用于评估皮肤疗效,PsA 改良 Sharp/van der Heijde 评分用于评估放射学进展。
临床怎么用
- 静脉戈利木单抗 2 mg/kg 可用于活动性银屑病关节炎的持续治疗,关节和皮肤疗效可维持至 1 年。
- 治疗期间需监测不良事件,包括严重不良事件、恶性肿瘤和死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The present study was undertaken to evaluate the safety and efficacy of intravenous (IV) golimumab in patients with active psoriatic arthritis (PsA) through 1 year. METHODS: GO-VIBRANT was a phase III, randomized, placebo-controlled trial of 480 adults with active PsA. Patients were randomized to receive IV placebo (n = 239) or golimumab 2 mg/kg (n = 241) at weeks 0, 4, and every 8 weeks, with placebo crossover to golimumab at weeks 24, 28, and every 8 weeks thereafter. Efficacy through week 52 was assessed using the American College of Rheumatology (ACR) ≥20%, 50%, or 70% improvement criteria (ACR20/50/70), and the Psoriasis Area and Severity Index ≥75% improvement criteria (PASI75). Radiographic progression was measured using the PsA-modified Sharp/van der Heijde score (SHS). Adverse events (AEs) were monitored through week 60. RESULTS: The primary and major secondary end points through week 24 were achieved. At week 52, 76.8% of patients in the golimumab group and 77.0% in the placebo-crossover group achieved an ACR20 response, 58.1% and 53.6%, respectively, achieved an ACR50 response, and 38.6% and 33.9%, respectively, achieved an ACR70 response. Among patients with ≥3% body surface area affected, 71.9% in the golimumab group and 60.6% in the placebo-crossover group achieved a PASI75 response at week 52. Mean change from baseline in total SHS at week 52 was -0.5 in the golimumab group and 0.8 in the placebo-crossover group. Through week 60, 50.9% of all golimumab-treated patients had ≥1 AE, and 5.2% had ≥1 serious AE. There were no opportunistic infections, 2 malignancies, and 1 death in patients treated with golimumab. CONCLUSION: Sustained improvements in joint and skin disease in patients with PsA were maintained through 1 year in the GO-VIBRANT study. No new safety signals for IV golimumab were identified.
引用
- Husni ME, Kavanaugh A, Murphy F, et al. Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2020. PMID: 30980514. doi:10.1002/acr.23905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。